In endometrial cancer models, pharmacologic blockade of Netrin-1 using the monoclonal antibody NP137 induces apoptosis, suppresses EMT, and reduces tumor burden in both preclinical and early-phase clinical settings [242]. The gene discussed is NTN1; the disease is neoplasm.